摘要
目的探讨阿糖胞苷在慢性粒细胞白血病(CML)中的应用。方法将我院2008年12月至2012年1月收治的68例确诊为慢性粒细胞白血病的患者随机分为治疗组和对照组。每组34例,两组均使用羟基脲(Hu)进行先期治疗,当患者的白细胞(WBC)<20.0×109/L,对照组采用干扰素进行治疗,治疗组给予干扰素联合阿糖胞苷治疗。对两组的血液学情况和细胞遗传学改变进行比较。结果治疗组和对照组外周WBC开始下降时间和下降至正常所需时间差异无统计学意义(P>0.05);与对照组比较,治疗组血液学缓解(CHR)和主要细胞遗传学的缓解率均显著提高(P<0.05)。结论阿糖胞苷联合干扰素治疗慢性粒细胞白血病疗效显著。
Objective To investigate the application of cytarabine on chronic myelogenous leukemia（CML）. Methods 68 patients diagnosed as chronic myelogenous leukemia from December 2008 to January 2012 were random- ly divided into treatment group and control group ,34 cases in each group, the two groups were treated with hydroxyurea （Hu） to the WBC 〈 20.0 × 109/L of patient. The control group was given interferon only, and the treatment group was treated with cytarabine on the basis of the control group. The hematologic and cytogenetic changes of the two groups were compared. Results The time when WBC began to fall and the time when WBC fell to normal range were no sig- nificantly difference in the two groups （ P 〉 0. 05 ）. The CHR and major cytogenetic response rate in treatment group were significantly higher than those in the control group （ P 〈 0.05 ）. Conclusion The clinical curative effect of cytara- bine combined with interferon on chronic myeloid leukemia patients was better.
出处
《实用药物与临床》
CAS
2013年第5期395-397,共3页
Practical Pharmacy and Clinical Remedies
